Novartis at ASH
Dec 02, 2020
Novartis 2020 ASH Annual Meeting Virtual Portal
Novartis presence at ASH:
Press releases
- Data from more than 65 abstracts showcase Novartis focus on delivering transformative innovation for blood cancers and serious hematologic diseases at ASH20
- New Novartis data from pivotal Phase III REACH3 study in chronic graft-versus-host disease presented at ASH20
- Novartis to present new analyses from ELARA and JULIET trials of CAR-T cell therapy for patients with certain advanced lymphomas at ASH20
- Exciting new late-breaker data from Novartis on novel, investigational STAMP inhibitor in chronic myeloid leukemia at ASH20
Our commitment to blood cancers and blood disorders: